Synthesis and immunomodulation of human lymphocyte proliferation and cytokine (interferon-γ) production of four novel malonitrilamides

Chemical Biology and Drug Design

Volumn 73, Issue 6, 2009, Pages 668-673

  Hadizadeh, Farzin ^a   Moallem, Seyed Adel ^a,b,c   Jaafari, Mahmoud Reza ^a,b   Shahab, Mahdi ^b   Alahyari, Maryam ^a   Rameshrad, Maryam ^c   Samiei, Afshin ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Immunomodulation; Interferon ; Leflunomide; Malonitrilamides; MTT assay; Synthesis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMIDE; CARBON DIOXIDE; CYCLOSPORIN; CYTOKINE; DRUG METABOLITE; ESTER; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MALONITRILAMIDE DERIVATIVE; N (3' CYANOBIPHENYL 4 YL) 2 CYANO 3 HYDROXYCROTONATE; N (4' CYANOBIPHENYL 4 YL) 2 CYANO 3 HYDROXYCROTONATE; N (BIPHENYL 4 YL) 2 CYANO 3 HYDROXYCROTONATE; O (BIPHENYL 4 YL) 2 CYANO 3 HYDROXYCROTONATE; PHYTOHEMAGGLUTININ; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL;

AMIDES; CELL PROLIFERATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; ISOXAZOLES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; NITRILES;

EID: 65849325334     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2009.00812.x     Document Type: Article

References (20)

1. Greene S., Watanabe K., Braatz-Trulson J., Lou L. (1995) Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 50 : 861 867.
2. Cherwinski H.M., Cohn R.G., Cheung P., Webster D.J., Xu Y.Z., Caulfield J.P., Young G.M., Nakano G., Ransom J.T. (1995) The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 275 : 1043 1049.
3. Cutolo M., Sulli A., Ghiorzo P., Pizzorni C., Craviotto C., Villaggio B. (2003) Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis 62 : 297 302.
4. Williams J.W., Mital D., Chong A., Kottayil A., Millis M., Longstreth J. et al. (2002) Experiences with leflunomide in solid organ transplantation. Transplantation 73 : 358 366.
5. Yao H.W., Li J., Chen J.Q., Xu S.Y. (2004) A 771726, the active metabolite of leflunomide, inhibits TNF-alpha and IL-1 from Kupffer cells. Inflammation 28 : 97 103.
6. Hausen B., Boeke K., Berry G.J., Gummert J.F., Christians U., Morris R.E. (1999) Potentiation of immunosuppressive efficacy by combining the novel leflunomide analog, HMR 279, with microemulsion cyclosporine in a rat lung transplant model. Transplantation 67 : 354 359.
7. Schorlemmer H.U., Kurrle R., Bartlett R.R. (1997) The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents. Drugs Exp Clin Res 23 : 167 173.
8. Schmouder R.L. (2000) Immunosuppressive therapies for the twenty-first century. Transplant Proc 32 : 1463 1467.
9. Birsan T., Dambrin C., Klupp J., Stalder M., Larson M.J., Fitzsimmons W.E. et al. (2003) In vivo pharmacokinetic and pharmacodynamic evaluation of the malononitrilamide FK778 in non-human primates. Transpl Int 16 : 354 360.
10. Kammerer F.J., Schleyerbach R. (1981) 5-Methylisoxazole-4-carboxylic- (4′-trifluoromethyl)-anilide, US Patent No. 4,284-786.
11. Tang P.C., Calif M. (1995) Compounds and methods for inhibiting hyper proliferative cell growth. US Patent No. 5,721,277.
12. Ramakrishan A., Gobind K., Neeraj K., Dnyaneshwar S. (2006) An improved process for preparation of leflunomide, WO Patent No./2007/086076.
13. Loveland B.E., Johns T.G., Mackay I.R., Vaillant F., Wang Z.X., Hertzog P.J. (1992) Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays. Biochem Int 27 : 501 510.
14. Sugiyama K., Arakawa K., Satoh H., Saito K., Takahashi K., Saito N. et al. (2006) Correlation between pharmacological efficacy of cyclosporine A and tacrolimus, evaluated by lymphocyte immunosuppressant-sensitivity test (LIST) with MTT assay procedure in renal transplant recipients. J Immunoassay Immunochem 27 : 195 205.
15. Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W. (2008) Current Protocols in Immunology. New York : John Wiley & Sons.
16. Slauson S.D., Silva H.T., Sherwood S.W., Morris R.E. (1999) Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Immunol Lett 67 : 179 183.
17. Dietert R.R., Lee J.E., Olsen J., Fitch K., Marsh J.A. (2003) Developmental immunotoxicity of dexamethasone: comparison of fetal versus adult exposures. Toxicology 194 : 163 176.
18. McHugh S.M., Rifkin I.R., Deighton J., Wilson A.B., Lachmann P.J., Lockwood C.M. et al. (1995) The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99 : 160 167.
19. Silva H.T. Jr., Morris R.E. (1997) Leflunomide and malononitriloamides. Expert Opin Investig Drugs 6 : 51 64.
20. Koch M.J., Brennan D.C. (2003) Leflunomide: is there a place for its use in transplantation? [Immunosuppression] Curr Opin Organ Transplant 8 : 317 322.